Asthma Management in Older Adults

Primary Recommendations

The American Academy of Family Physicians recommends initiating low-dose inhaled corticosteroids (ICS) at 200-250 μg/day of beclomethasone equivalent for older adults with mild persistent asthma, with as-needed short-acting beta-agonist (SABA) for quick relief 1, 2
Low-dose ICS represents the preferred Step 2 therapy for mild persistent asthma in adults aged 12 years and older, including older adults, according to the American Academy of Family Physicians and the Journal of Allergy and Clinical Immunology 1, 3

For older adults aged 12 years and older who may have adherence concerns with daily therapy, as-needed ICS plus SABA used concomitantly represents an acceptable alternative, as recommended by the Journal of Allergy and Clinical Immunology 3
This intermittent approach involves 2-4 puffs of albuterol followed by 80-250 μg of beclomethasone equivalent every 4 hours as needed for asthma symptoms, with no differences in asthma control, quality of life, or exacerbation frequency between daily low-dose ICS and intermittent ICS when used with SABA 3

Leukotriene receptor antagonists (montelukast or zafirlukast) are easier to use with high compliance rates but less effective than ICS, according to the American Academy of Family Physicians 1

SABA use frequency serves as the primary indicator for treatment adequacy, with use more than 2 days per week for symptom relief indicating inadequate control and need to step up to Step 3 therapy, as recommended by the American Academy of Family Physicians 1, 4
Assess symptom control, medication adherence, and environmental triggers at every visit, according to the American Academy of Family Physicians 1, 4

Pay particular attention to comorbidities (COPD overlap, cardiovascular disease, osteoporosis) that may complicate asthma management in older adults, as recommended by the American Geriatrics Society 4

Add a long-acting beta-agonist (LABA) to low-dose ICS rather than increasing ICS dose, as recommended by the American Thoracic Society, providing greater improvement in lung function, symptoms, and exacerbation reduction 2, 5
LABAs must never be used as monotherapy due to increased risk of severe exacerbations and deaths, according to the American Academy of Family Physicians and the American Thoracic Society 1, 2, 5